Home » Clinical Trials » Therapeutic Areas
Therapeutic Areas: Psychiatry/Psychology
Disease Category: Depression (Major/Severe)
Trial Information
A 12-Week Randomized, Double-Blind, Placebo-Controlled, Parallel-Sequential Trial of Ziprasidone as Monotherapy for Major Depressive Disorder
Ziprasidone (Geodon) Monotherapy for MDD
The purpose of this study is to test the effectiveness, safety, and tolerability of ziprasidone (Geodon) as a treatment for Major Depressive Disorder (MDD). Ziprasidone has been approved by the U.S. Food and Drug Administration (FDA) for the treatment of bipolar disorder and schizophrenia, but in this study it is being tested for its effectiveness in depression.
As a subject in this research study you will be randomly assigned by chance, like the flip of a coin, to one of three groups. Subjects in the first group will receive 12 weeks of ziprasidone, those in the second group will receive 12 weeks of placebo (looks like the study drug but contains no active medication), and those in the third group will receive 6 weeks of placebo followed by 6 weeks of ziprasidone. You will have a 5 in 8 chance of receiving ziprasidone at some point in the study.
It will take you about 14 weeks to complete this study. During this time you will be asked to make 14 study visits. At the conclusion of the study, you will be offered 3 months of follow-up care at no cost with the study physicians on staff.
If you are interested in this study, please contact Carrie Brintz at 617-726-5805 or cbrintz@partners.org
Carrie E Brintz
Depression Clinical and Research Program
50 Staniford Street
Suite 401
Boston, MA 02114
Phone: 617-726-5805
EMail: cbrintz@partners.org
View Google Map
If you would like to learn more about participating in this study, please send an e-mail message using the form below.
DISCLAIMER: This site is run by CenterWatch, a publishing company that focuses on the
clinical trials industry. The information provided in this service is designed
to help patients find clinical trials that may be of interest to them, and to
help patients contact the centers conducting the research. CenterWatch is
neither promoting this research nor involved in conducting any of these
trials.
